Trendovi u istraživanju i razvoju lijekova – novi lijekovi u 2021. godini

master's thesis

• Title (english): Trends in drug research and development - new medicines in 2021
• Author: Ana Štrbac
• Mentor: Lidija Bach-Rojecky (mentor)
• Committee member: Lidija Bach-Rojecky (predsjednik povjerenstva)
• Committee member: Marijana Zovko Končić (član povjerenstva)
• Committee member: Monika Barbarić (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmacology); Zagreb
• Defense date and country: 2022-11-21, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Ovaj pregledni diplomski rad sažeto prikazuje lijekove koji su odobreni u 2021. godini od strane američke i europske regulatorne agencije za lijekove (FDA i EMA), te naglašava važnost daljnjeg ulaganja u razvoj novih lijekova. Ovim diplomski radom nisu obuhvaćeni lijekovi za liječenje malignih bolesti, kao niti cjepiva . Razvoj novih lijekova u svrhu unaprjeđivanja zdravstvene skrbi oboljelih uključuje multidisciplinarni pristup i suradnju znanstvenika različitih profila, od molekularnih biologa, genetičara, kemičara, biostatičara, do farmakologa, liječnika i farmaceuta. Od 50 odobrenih lijekova u SAD-u, najviše ima malih molekula, zatim bioloških lijekova, od čega su najzastupljenija monoklonska protutijela, a od terapijskih područja najzastupljeniji su onkološki lijekovi . U 2021. godini odobren je lijek koji je mala inteferirajuća RNA, čime se otvara prostor za post-transkripcijsko utišavanje gena kao terapijski pristup u liječenju određenih bolesti i stanja. Odobreni su i četiri bioslična lijeka te tako ti lijekovi postaju dostupniji većem broju pacijenata. Ovaj broj od 50 novih lijekova govori u prilog ulaganja u prevenciju, liječenje i unaprjeđenje skrbi o bolesnicima. Lijek koji je dostupan svima, učinkovit i siguran, težnja je svih uključenih u skrb o oboljelima.

Abstract (english)

The review thesis summarizes the drugs approved in 2021 by the US and European Medicines Regulatory Agency (FDA and EMA). It highlights the importance of further investment in the development of new drugs. Medicines for the treatment of malignant diseases, as well as vaccines were not included in this thesis. Development of new drugs for the purpose of improving health care of patients involves a multidisciplinary approach and cooperation of scientists of various profiles, from molecular biologists, geneticists, chemists, biostatisticians, to pharmacologists, doctors and pharmacists. Of the 50 approved drugs in the USA, the most represented are small molecules, followed by biological drugs of which monoclonal antibodies are the most represented, of therapeutic areas oncology drugs are the most represented. In 2021 a small interfering RNA drug was approved, which opens the way for post transcriptional gene silencing as therapeutic approach in the treatment of certain diseases and conditions. Four biosimilar drugs have also been approved, making these drugs more accesssible to a larger number of patients. This number of 50 new medicines speaks in favor of investment in prevention, treatment and improvement of patient care. Medicine that is available to everyone effective and safe is the aspiration of everyone involved in the care of patients.

• Keywords: novi lijekovi; odobravanje lijekova; agencije za lijekove
• Keywords (english): new drugs; approval of drugs; medicines agencies
• Language: croatian
• URN:NBN: urn:nbn:hr:163:528873
• Study programme: Title: Pharmacy; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2022-11-24 13:45:15